CN102351842B - 甲磺酸伊马替尼的f、g、h、i 和k晶形 - Google Patents

甲磺酸伊马替尼的f、g、h、i 和k晶形 Download PDF

Info

Publication number
CN102351842B
CN102351842B CN201110232553.6A CN201110232553A CN102351842B CN 102351842 B CN102351842 B CN 102351842B CN 201110232553 A CN201110232553 A CN 201110232553A CN 102351842 B CN102351842 B CN 102351842B
Authority
CN
China
Prior art keywords
crystalline form
formula
compound
methanesulfonic acid
added methanesulfonic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201110232553.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN102351842A (zh
Inventor
M·马兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0524062A external-priority patent/GB0524062D0/en
Priority claimed from GB0524061A external-priority patent/GB0524061D0/en
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN102351842A publication Critical patent/CN102351842A/zh
Application granted granted Critical
Publication of CN102351842B publication Critical patent/CN102351842B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201110232553.6A 2005-11-25 2006-11-23 甲磺酸伊马替尼的f、g、h、i 和k晶形 Expired - Fee Related CN102351842B (zh)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
GB0524062A GB0524062D0 (en) 2005-11-25 2005-11-25 Organic compounds
GB0524061.9 2005-11-25
GB0524061A GB0524061D0 (en) 2005-11-25 2005-11-25 Organic compounds
GB0524062.7 2005-11-25
US74001605P 2005-11-28 2005-11-28
US74001705P 2005-11-28 2005-11-28
US74001805P 2005-11-28 2005-11-28
US60/740,017 2005-11-28
US60/740,016 2005-11-28
US60/740,018 2005-11-28

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2006800440077A Division CN101312960B (zh) 2005-11-25 2006-11-23 甲磺酸伊马替尼的f、g、h、i和k晶形

Publications (2)

Publication Number Publication Date
CN102351842A CN102351842A (zh) 2012-02-15
CN102351842B true CN102351842B (zh) 2014-07-23

Family

ID=37847165

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201110232553.6A Expired - Fee Related CN102351842B (zh) 2005-11-25 2006-11-23 甲磺酸伊马替尼的f、g、h、i 和k晶形

Country Status (13)

Country Link
US (6) US7893076B2 (enExample)
EP (3) EP2578580A1 (enExample)
JP (2) JP5844508B2 (enExample)
KR (4) KR20080078804A (enExample)
CN (1) CN102351842B (enExample)
AU (2) AU2006316823A1 (enExample)
BR (1) BRPI0618993A2 (enExample)
CA (3) CA2824307C (enExample)
EC (1) ECSP088473A (enExample)
MY (1) MY146403A (enExample)
NO (1) NO20082684L (enExample)
UY (1) UY29964A1 (enExample)
WO (1) WO2007059963A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20051096A1 (es) 2004-02-04 2006-01-23 Novartis Ag Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil]-benzamida
JP5844508B2 (ja) * 2005-11-25 2016-01-20 ノバルティス アーゲー メシル酸イマチニブのｆ結晶形
US20090087489A1 (en) * 2007-09-25 2009-04-02 Bella Gerber Imatinib compositions
RU2365587C1 (ru) * 2008-02-22 2009-08-27 Закрытое Акционерное Общество "Фарм-Синтез" Рентгеноаморфная безводная модификация 4-[(4-метил-1-пиперазинил)метил]-n-[4-метил-3-[[4-(3-пиридинил)-2-пиримидинил]-амино]-фенил]бензамида метансульфоната и способ ее получения
CZ2009570A3 (cs) 2009-08-26 2011-03-09 Zentiva, K. S. Príprava, stabilizace a využití polymorfu imatinib mesylátu pro vývoj lékových forem
PL389357A1 (pl) 2009-10-22 2011-04-26 Tomasz Koźluk Sole imatinibu z pochodnymi kwasów winowych i sposób ich wytwarzania
JP2013519665A (ja) 2010-02-15 2013-05-30 リライアンス ライフ サイエンシズ ピーヴィーティー リミティッド メシル酸イマチニブのα形の製造方法
PL390611A1 (pl) 2010-03-04 2011-09-12 Tomasz Koźluk Sposób otrzymywania polimorficznej formy alfa i nowa forma polimorficzna mesylanu imatinibu
WO2012090221A1 (en) 2010-12-29 2012-07-05 Cadila Healthcare Limited Novel salts of imatinib
EP2604596A1 (en) * 2011-12-16 2013-06-19 Deva Holding Anonim Sirketi Polymorphs of imatinib
EP2864313A1 (en) 2012-06-22 2015-04-29 Basf Se Multicomponent crystals comprising imatinib mesilate and selected co-crystal formers
KR101242955B1 (ko) * 2012-06-25 2013-03-12 제일약품주식회사 이마티닙 메실레이트 결정형 α의 제조 방법
ES2683361T3 (es) 2013-05-14 2018-09-26 Hetero Research Foundation Composiciones de Imatinib
US10478290B2 (en) * 2013-11-26 2019-11-19 Children's Medical Center Corporation Expandable stent valve
WO2018089404A1 (en) 2016-11-11 2018-05-17 Mallinckrodt Nuclear Medicine Llc Processes for generating germanium-68 with reduced volatiles

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1264375A (zh) * 1997-07-18 2000-08-23 诺瓦提斯公司 N－苯基－2－嘧啶胺衍生物的结晶变体,其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (enExample) 1992-04-03 1994-06-21 Ciba Geigy Ag
US20060073185A1 (en) 2002-12-13 2006-04-06 Bausch & Lomb Incorporated Method and composition for contact lenses
TR200504337T1 (tr) * 2003-06-02 2006-12-21 Hetero Drugs Limited Imatinib mezilat'ın yeni polimorfları
PE20051096A1 (es) 2004-02-04 2006-01-23 Novartis Ag Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil]-benzamida
CA2555804C (en) * 2004-02-11 2012-06-26 Natco Pharma Limited Polymorphic form of imatinib mesylate and a process for its preparation
UA84462C2 (ru) * 2004-04-02 2008-10-27 Институт Фармацевтични Полиморфные модификации кислотно-аддитивных солей иматиниба с метансульфоновой кислотой
WO2005117885A1 (en) 2004-06-04 2005-12-15 Bioniche Life Sciences Inc. Use of imatinib to treat liver disorders and viral infections
KR101348625B1 (ko) * 2004-09-02 2014-01-07 씨아이피엘에이 엘티디. 이매티닙 메실레이트의 안정한 결정형 및 그의 제조방법
WO2006048890A1 (en) * 2004-11-04 2006-05-11 Sun Pharmaceutical Industries Limited Imatinib mesylate crystal form and process for preparation thereof
WO2006054314A1 (en) * 2004-11-17 2006-05-26 Natco Pharma Limited Polymorphic forms of imatinib mesylate
US9804295B2 (en) 2005-05-05 2017-10-31 Novartis Ag Ophthalmic devices for sustained delivery of active compounds
GB0511066D0 (en) 2005-05-31 2005-07-06 Novartis Ag Organic compounds
UY29766A1 (es) * 2005-08-26 2007-03-30 Novartis Ag Formas cristalinas delta y épsilon de mesilato de imatinib
JP5844508B2 (ja) * 2005-11-25 2016-01-20 ノバルティス アーゲー メシル酸イマチニブのｆ結晶形

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1264375A (zh) * 1997-07-18 2000-08-23 诺瓦提斯公司 N－苯基－2－嘧啶胺衍生物的结晶变体,其制备方法和应用

Also Published As

Publication number Publication date
JP2009517353A (ja) 2009-04-30
BRPI0618993A2 (pt) 2011-09-20
US8198289B2 (en) 2012-06-12
KR20130137721A (ko) 2013-12-17
US8846706B2 (en) 2014-09-30
AU2011201286A1 (en) 2011-04-07
CA2824301C (en) 2016-01-12
CA2824307C (en) 2016-03-29
KR20080078804A (ko) 2008-08-28
US20110171301A1 (en) 2011-07-14
JP5844508B2 (ja) 2016-01-20
NO20082684L (no) 2008-08-15
US8507515B2 (en) 2013-08-13
KR20130141712A (ko) 2013-12-26
EP1960380A1 (en) 2008-08-27
US8592440B2 (en) 2013-11-26
CA2824301A1 (en) 2007-05-31
UY29964A1 (es) 2007-06-29
AU2006316823A1 (en) 2007-05-31
KR20130140909A (ko) 2013-12-24
US20130224288A1 (en) 2013-08-29
US7893076B2 (en) 2011-02-22
US8633213B2 (en) 2014-01-21
CA2628330C (en) 2015-06-16
US20080268040A1 (en) 2008-10-30
CN102351842A (zh) 2012-02-15
WO2007059963A1 (en) 2007-05-31
CA2824307A1 (en) 2007-05-31
EP2578580A1 (en) 2013-04-10
CA2628330A1 (en) 2007-05-31
MY146403A (en) 2012-08-15
US20120015027A1 (en) 2012-01-19
US20120226038A1 (en) 2012-09-06
EP2546248A1 (en) 2013-01-16
ECSP088473A (es) 2008-06-30
JP2014074067A (ja) 2014-04-24
US20120015955A1 (en) 2012-01-19

Similar Documents

Publication Publication Date Title
CN102002035B (zh) 甲磺酸伊马替尼的δ和ε晶形
US12227481B2 (en) Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
CN102351842B (zh) 甲磺酸伊马替尼的f、g、h、i 和k晶形
US8552038B2 (en) Crystalline forms of thiazolidinedione compound and its manufacturing method
TWI815820B (zh) ２－（５－（４－（２－嗎啉乙氧基）苯基）吡啶－２－基）－ｎ－芐乙醯胺之固態形式
CN101312960B (zh) 甲磺酸伊马替尼的f、g、h、i和k晶形
CN102666528A (zh) 晶体cdc7 抑制剂盐
HK40026069A (en) Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
HK40026069B (en) Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
MX2008006696A (en) F,g,h,i and k crystal forms of imatinib mesylate
HK1177737A (en) Crystal form h of imatinib mesylate

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent for invention or patent application
CB02 Change of applicant information

Address after: Basel

Applicant after: Novartis Ag

Address before: Basel

Applicant before: Novartis AG

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: NOVARTIS AG TO: NOVARTIS CO., LTD.

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140723

Termination date: 20161123